TNL Mediagene: TNL Mediagene's Business Insider Taiwan Surpasses 1.2 Million Monthly Website Page Views Less Than One Year After Launch, Announces Two Original Programs to Drive New Commercial Growth

TNL Mediagene (NASDAQ: TNMG) said it completed full repayment of a senior convertible note to 3i, LP, with the final payment made July 8, 2026. The Second Note had $1,666,667 principal and $150,000.03 accrued interest, repaid in shares totaling 3,381,700. The company and 3i also terminated the related securities purchase agreement, leaving no convertible notes outstanding under the Nasdaq-listing facility.

TNL Mediagene (NASDAQ: TNMG) said it fully repaid a senior convertible note to 3i, LP, completing the final payment on July 8, 2026. The Second Note had $1,666,667 principal and $150,000.03 accrued interest, repaid with 3,381,700 shares. The company and 3i also terminated the related note purchase agreement, leaving no convertible notes outstanding under the facility.

Meta Platforms (META) launched Meta One, a subscription service offering expanded AI features across Facebook, Instagram, and WhatsApp. Plans range from $7.99 to $499 per month. The move aims to diversify revenue as Meta faces high AI infrastructure costs and relies heavily on advertising. Meta's Q2 revenue rose 28% to $60.8B, but net income fell 15%. Analysts expect Q3 revenue of $73.66B.

Biogen Inc. (BIIB) reported that EMPAVELI (pegcetacoplan) showed a 75% relative reduction in proteinuria in adolescents with C3G or primary IC-MPGN in a Phase 3 study. The FDA recently expanded EMPAVELI's label to include reducing kidney function loss in patients aged 12 and older. The drug is the only approved treatment for these conditions in adolescents, according to the company.

AbbVie's atogepant (Qulipta) showed significant reductions in menstrual migraine days in a Phase 3 study. Patients saw a 1.2-day reduction vs. 0.4 days for placebo. The study met all secondary endpoints, including headache days and functional disability. AbbVie plans to assess long-term effects in an extension study. No new safety concerns were reported.

Boeing's CEO Kelly Ortberg stated that 777X certification testing will likely extend into 2027 due to unresolved engine mid-seal issues, delaying ETOPS authorization. GE Aerospace is working on a fix, with both companies planning 2027 deliveries. Labor negotiations also pose a risk to certification timelines. The 777X is seven years behind schedule, with airlines like Emirates and Lufthansa awaiting ETOPS for long-haul routes.